Financial Performance - Zentalis Pharmaceuticals reported a net loss of $137.1 million for the year ended December 31, 2025, compared to a net loss of $165.9 million in 2024, representing a 17.3% decrease in losses [19]. - The net loss per common share for 2025 was $1.91, an improvement from $2.33 in 2024 [19]. - The total operating expenses for 2025 were $152.8 million, down from $258.6 million in 2024, marking a 41% reduction [19]. - The company reported no revenues from licensing and sales of intellectual property in 2025, compared to $67.4 million in 2024 [19]. Research and Development - Research and development expenses decreased to $107.3 million in 2025 from $167.8 million in 2024, a reduction of 64.5 million or 36.1% [12]. - The completion of enrollment for the DENALI Part 2a trial is expected to support dose confirmation in the first half of 2026, with topline results anticipated by year-end 2026 [4]. - The company plans to initiate the Phase 3 ASPENOVA trial in the first half of 2026, comparing azenosertib to standard-of-care chemotherapy for Cyclin E1-positive PROC patients [5]. - Zentalis is also exploring the combination of azenosertib with bevacizumab in the ongoing MUIR study for earlier treatment settings in ovarian cancer [5]. Cash Position - As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $245.9 million, providing a cash runway into late 2027 [5]. Administrative Expenses - General and administrative expenses significantly decreased to $37.7 million in 2025 from $87.1 million in 2024, a decline of 56.7% [12].

Financial Performance - The company reported net losses of $19.5 million for the year ended December 31, 2025, a decrease of 11% from a net loss of $21.8 million in 2024[177]. - The company incurred losses from operations of $20.9 million and used $15.6 million in cash for operating activities in 2025, a decrease from $16.8 million in 2024[182]. Expenses - Research and development expenses decreased by $2.2 million or 19%, to $10.0 million in 2025 from $12.2 million in 2024, primarily due to lower costs related to the VenoValve study[179]. - Selling, general and administrative expenses decreased by $0.7 million or 6%, to $10.9 million in 2025 from $11.6 million in 2024, driven by non-recurring legal costs incurred in 2024[180]. Cash Position - The cash balance as of December 31, 2025, was $3.1 million, with total cash and investments amounting to $28.2 million[182]. - The company anticipates an increase in cash burn rate to between $4 million and $5 million per quarter in 2026, while having sufficient cash to fund operations through mid-2027[185]. Product Development - The enVVe System, a next-generation non-surgical venous valve product, has completed pre-clinical testing and discussions with the FDA regarding the pivotal trial are expected to begin in 2026[173]. - The company is focused on obtaining FDA approval for the enVVe System, with no current devices approved for surgical or non-surgical replacement venous valves[172]. - The company will continue to incur costs related to clinical trials for the VenoValve and enVVe System as it seeks regulatory approval for its product candidates[183]. Corporate Actions - A reverse stock split of one-for-thirty-five (1:35) was approved and became effective on January 20, 2026[175].

Financial Position - As of December 31, 2025, the company had approximately $10.1 million in cash and cash equivalents, including restricted cash[115]. - As of December 31, 2025, the company's cash and cash equivalents were approximately $10.1 million, including restricted cash[172]. - In January 2026, the company generated proceeds of $29.3 million from the issuance of shares of common stock[115]. - As of March 18, 2026, the company has $18.2 million in convertible notes outstanding, convertible at a weighted average rate of $1.28 per share, and $13.8 million in preferred stock convertible at a weighted average rate of $1.25 per share[198]. - If all outstanding convertible notes and preferred shares are converted, the company would need to issue approximately 25.7 million shares of common stock, leading to potential dilution for existing shareholders[199]. Risks and Challenges - The company may face risks associated with debt financing, including insufficient cash flow to meet principal and interest payments[117]. - The company relies on a limited number of third-party manufacturers, which could adversely affect growth and profitability if relationships dissolve[122]. - The company is exposed to risks associated with shipping products from China, including customs duties and trade restrictions[125]. - The company may face challenges in accurately estimating inventory and production requirements for its smart products[124]. - The company may not be able to successfully implement cost reduction measures, which could adversely affect financial condition and results of operations[124]. - The company may issue dilutive securities and incur debt obligations in connection with acquisitions, which could negatively impact profitability[131]. - The company's product business may become significantly dependent on contracts awarded through competitive bidding processes, which involve substantial time and resources with no guarantee of contract awards[132]. - Failure to consistently win new contract awards could materially and adversely affect the company's growth strategy, financial condition, and results of operations[133]. - The company faces risks related to the protection of its intellectual property, which could adversely affect its business and financial condition if not adequately protected[135]. - The expiration or loss of patent protection may impact future revenues and operating income, as the company relies heavily on intellectual property protections[140]. - The company faces risks from unstable market conditions, including high inflation, interest rates, and geopolitical factors, which may adversely affect financial performance and stock price[170]. - The company may face challenges in securing necessary financing due to deteriorating credit and financial markets, which could hinder growth strategies[170]. - The company is vulnerable to economic and political conditions in Israel, which may impact operations and revenues[173]. - Cybersecurity incidents at third-party providers could lead to operational disruptions and financial harm, as the company relies on these vendors for critical services[178]. - The company is subject to governmental regulations regarding data privacy and cybersecurity, which could increase operational costs and affect business performance[188]. - The company faces risks related to compliance with evolving data protection laws, which could result in fines and damage to reputation if not adhered to[190]. Operational Considerations - The company acquired Belami, an e-commerce platform, in 2023, which may require significant resources and investments[130]. - The company may need to hire and train a sizable number of employees for full-scale commercial manufacturing operations[123]. - Compliance with quality and safety standards is essential, and failure to meet these standards could lead to product recalls and negatively affect financial performance[141]. - The company relies on third parties for product distribution, which may limit control over sales efforts and expose the company to financial risks if distributors face difficulties[145]. - The company strives to obtain certifications for its products, and failure to achieve or maintain these certifications could adversely impact net sales[149]. - Defects in the mobile application and its underlying technology may lead to adverse publicity and financial repercussions, affecting market acceptance and customer claims[150]. - The company is implementing a new enterprise resource planning (ERP) system, which is critical for operational efficiency and may require significant financial and human resources[192]. - The company is incorporating artificial intelligence capabilities into its product offerings, which may present operational and reputational risks if not managed properly[182]. - The evolving regulatory landscape surrounding AI technologies may impose significant operational costs and limit the company's ability to utilize AI effectively[182]. Compliance and Governance - The Company incurs increased costs as a public entity, including legal and compliance expenses, which could divert management's attention from business operations[160]. - Compliance with the Sarbanes-Oxley Act and other regulations imposes significant requirements on the Company, potentially increasing legal and financial compliance costs[161]. - The Company must maintain effective internal controls over financial reporting, and any deficiencies could adversely affect investor confidence and stock value[166]. - A material weakness in internal controls could prevent timely and accurate financial statements, leading to a decline in stock price and potential regulatory sanctions[168]. - The Company faces inherent limitations in its internal control systems, which may not prevent all errors or fraud, potentially resulting in material misstatements[169]. - The concentration of voting power among executive officers and preferred stockholders may limit the influence of common stockholders on corporate matters[203]. - The company's articles of incorporation and bylaws include provisions that may inhibit non-negotiated mergers or other business combinations[211]. - The board of directors has the authority to designate and issue shares of preferred stock without requiring stockholder vote or approval[211]. - A majority stockholder vote is required to remove directors from office, or a majority of the board of directors if for cause[211]. - There are limitations on who may call special meetings of stockholders, which could further impact governance[211]. Market Conditions - The stock price has experienced volatility due to fluctuations in the equity markets, which may not correlate with the company's actual operating performance[171]. - The company’s stock price has been volatile and may continue to fluctuate significantly due to various uncontrollable factors[196]. - Market conditions, including inflation and geopolitical issues, may negatively impact the company's financial condition and share price[209]. - The company may incur additional costs to comply with cybersecurity regulations, which are becoming increasingly complex and unpredictable[189]. - The company has anti-takeover provisions in its charter documents and under Florida law that could discourage or delay a change in control, potentially affecting the trading price of its common stock[211].

Financial Performance - The net loss for the year ended December 31, 2025, was $48.3 million, or $0.49 per share, compared to a net loss of $27.5 million, or $1.16 per share in 2024, indicating a year-over-year increase in net loss of 75.5%[5] - Net loss for the year ended December 31, 2025, was $48,259,189, compared to a net loss of $27,519,886 in 2024, representing an increase of 75%[19] - Cash flows from operating activities resulted in a net cash used of $27,786,464 in 2025, up from $19,148,067 in 2024, indicating a 45% increase in cash outflow[19] - The accumulated deficit increased to $142.7 million as of December 31, 2025, from $94.4 million in 2024, reflecting a rise of 51%[15] Cash and Securities - As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $178.8 million, up from $97.5 million as of December 31, 2024, representing an increase of approximately 83%[5] - Cash and cash equivalents at the end of 2025 were $139,220,208, significantly up from $56,490,579 at the end of 2024, marking a 147% increase[19] - Proceeds from the issuance of common stock, pre-funded warrants, and warrants amounted to $107,617,495 in 2025, compared to $103,477,668 in 2024, showing a 4% increase[19] - Net cash provided by financing activities was $108,462,963 in 2025, compared to $103,477,668 in 2024, reflecting a 5% increase[19] - Purchases of investments in marketable securities were $39,094,847 in 2025, down from $60,455,103 in 2024, indicating a 35% decrease[19] - Maturities of investments in marketable securities increased to $41,600,000 in 2025 from $23,450,902 in 2024, representing a 77% increase[19] Expenses - Research and development expenses rose to $29.8 million in 2025 from $17.2 million in 2024, reflecting a 73.5% increase, which includes a $7.4 million non-cash write-off related to the acquisition of CorHepta[6] - Selling, general and administrative expenses increased to $23.6 million in 2025 from $11.4 million in 2024, marking a 106.1% rise, which includes $1.0 million in severance expenses[7] - Stock-based compensation expense rose to $15,309,924 in 2025, compared to $8,140,617 in 2024, which is an increase of 88%[19] - The write-off of in-process research and development was $7,357,294 in 2025, with no such expense recorded in 2024[19] Clinical Development - The Company is advancing IKT-001 into a global pivotal Phase 3 study in Pulmonary Arterial Hypertension (PAH), named IMPROVE-PAH, with approximately 140 patients in Part A and 346 patients in Part B[4] - The IMPROVE-PAH study is expected to be conducted at up to approximately 180 sites worldwide, with regulatory submissions filed in over 20 countries[9] - The Company has received confirmation of acceptance under the FAST-EU initiative, which aims to accelerate the approval of multinational clinical trials, potentially reducing authorization timelines to a maximum of 10 weeks[9] Assets - The total assets as of December 31, 2025, were $181.2 million, compared to $98.6 million as of December 31, 2024, indicating a growth of approximately 83.7%[15]

Business Model and Revenue Generation - The company is highly dependent on the successful development, marketing, and sale of its respiratory support products, which are critical to its business model[66]. - The company anticipates revenue generation through strategic relationships and distribution agreements, particularly with Glo-Med Networks Inc.[70]. - The company has executed various distribution agreements in different geographic regions, but these are subject to regulatory approvals, which may delay revenue realization[80]. - Future revenue generation will depend on market acceptance, pricing, and reimbursement from third-party payors for the company's products, which are currently under development[136]. - The company has not generated significant revenue from product sales and may never achieve profitability, as its ability to generate revenue relies on successful completion of product development and obtaining necessary regulatory approvals[137]. Regulatory and Compliance Challenges - The company may face challenges in obtaining regulatory approvals for its products, which could adversely impact its revenue and market expansion efforts[75]. - The company must maintain compliance with extensive government regulations, and failure to do so could result in enforcement actions that adversely affect its business operations[149]. - The company is subject to ongoing regulatory requirements even after obtaining clearance, which could result in increased costs or lower sales if compliance is not maintained[163]. - Regulatory changes could impose additional requirements that may delay the ability to obtain new clearances or approvals[165]. - The company must ensure that third-party manufacturers comply with applicable regulations to avoid delays in product delivery and potential enforcement actions[169]. Financial Condition and Funding - The company has incurred accumulated losses of approximately $80 million as of December 31, 2025, raising substantial doubt about its ability to continue as a going concern[131]. - The company has not generated significant revenues from its activities and has incurred substantial operating losses since its inception[131]. - The management expects to continue generating substantial operating losses and will primarily fund operations through current financial resources, product sales, and additional capital raises[131]. - As of December 31, 2025, the company had approximately $3.1 million in cash and cash equivalents, with a working capital of approximately $1.6 million, indicating a need for substantial additional funding to sustain operations[141]. - The company expects its existing cash and cash equivalents will be sufficient to fund operating expenses and capital requirements for the next six months, but substantial additional capital will be required for the next twelve months[247]. Competition and Market Risks - The company faces intense competition from established players in the medical device industry, which have greater resources and market share[96][97]. - Competitors may offer significant discounts, forcing the company to lower prices or offer favorable terms, impacting revenue potential[100]. - The company operates in a market characterized by rapid technological change, which may render its current or future products obsolete if it fails to innovate[76]. Intellectual Property Risks - The company faces risks related to intellectual property, including the potential inability to secure effective patent rights, which could hinder competitive positioning[208]. - Changes in patent laws could increase uncertainties and costs associated with the prosecution and enforcement of patents, potentially affecting the company's business[220]. - The company may be involved in costly and time-consuming lawsuits to protect its intellectual property, which could distract management and divert resources[221]. - The company may not be able to protect its intellectual property rights globally due to high costs and varying legal protections in different jurisdictions[226]. Operational and Workforce Challenges - The company has a small workforce of 37 full-time employees, and its future growth depends on retaining key personnel, particularly its CEO[91]. - The company may face difficulties in recruiting additional employees and consultants, which could disrupt operations[92]. - Management may need to divert attention from day-to-day activities to manage growth, potentially leading to operational mistakes and increased expenses[93]. International Operations and Political Risks - International expansion poses various risks, including regulatory approvals and compliance with multiple laws[94]. - The company’s operations may be adversely affected by political, economic, and military instability in Israel, including ongoing conflicts with Hamas and Hezbollah[250]. - The company has had employees called up for military service due to the current conflict, which may disrupt operations[255]. - The company may face increased operational risks due to potential boycotts, divestment, and sanctions against Israeli companies[256]. Market Dynamics and Legislative Changes - The U.S. Supreme Court reversed a decision denying $12 billion in "risk corridor" funding, impacting potential revenue streams for the company[191]. - The Inflation Reduction Act of 2022 extends enhanced subsidies for health insurance coverage in PPACA marketplaces through plan year 2025, which may affect the company's market dynamics[199]. - Medicare payment reductions of 2% per fiscal year, effective since April 1, 2013, will remain in effect until 2031, potentially impacting revenue from government programs[197]. - Legislative developments in the EU may impose additional requirements that could increase operating costs and delay marketing approvals for product candidates[192]. Shareholder and Securities Issues - The company received notices from Nasdaq regarding non-compliance with minimum bid price requirements, risking delisting[113][114]. - A potential delisting from Nasdaq could adversely affect the liquidity and market price of the company's shares[115]. - The trading price of the company's Ordinary Shares and Warrants has been volatile since the IPO in July 2021, influenced by broader market conditions and industry factors[231]. - Future sales of Ordinary Shares may lead to a decline in the market price of the company's securities, particularly if substantial amounts are sold on Nasdaq[233]. Future Outlook and Strategic Plans - The company plans to seek additional capital through various means, including private and public equity offerings, which may dilute existing shareholders' interests[146]. - Future acquisitions or strategic partnerships may increase capital requirements, dilute shareholders, and incur additional risks[117]. - The company expects significant increases in research and development expenses due to planned expanded studies and ongoing product development, leading to continued operating losses for the foreseeable future[135].

Financial Performance - For the year ended December 31, 2025, the company generated revenues of $359,700, a decrease of 10.3% from $401,000 in 2024[373]. - The company reported a net loss of $14.2 million for 2025, compared to a net loss of $8.98 million in 2024, representing a 58.5% increase in losses[372]. - As of December 31, 2025, the company had a working capital deficit of $586,029, a significant decrease from a working capital surplus of $7,395,815 in 2024[383]. - The company anticipates continued net losses and negative cash flows from operations as it executes its development plans for 2026 and beyond[372]. Expenses - Research and development expenses increased by 51% to $10,094,671 in 2025, up from $6,706,913 in 2024, primarily due to costs associated with the Phase 2 clinical trial[375]. - General and administrative expenses rose by 13% to $5,888,317 in 2025, compared to $5,221,209 in 2024, driven by increased stock-based compensation and headcount costs[377]. Cash Flow - For the year ended December 31, 2025, net cash used in operating activities was $10,788,963, primarily due to funding a net loss of $14,241,975[393]. - Net cash provided by investing activities was $8,897,470 for the year ended December 31, 2025, mainly from the sale of marketable securities which provided $11,692,686[394]. - Net cash provided by financing activities was $2,854,791 for the year ended December 31, 2025, due to net proceeds from common stock issuance[395]. - The company reported a net cash increase of $963,298 for the year ended December 31, 2025, compared to a decrease of $336,487 in 2024[392]. - The company experienced a significant increase in cash from investing activities in 2025 compared to 2024, rising from $514,529 to $8,897,470[394]. - The company’s net cash provided by financing activities decreased from $7,379,330 in 2024 to $2,854,791 in 2025[395]. Funding and Capital - The company sold 965,424 shares under an At The Market Offering Agreement, raising approximately $2.0 million in gross proceeds during 2025[369]. - The company expects to require significant additional funding to complete clinical trials and implement other programs, raising concerns about its ability to continue as a going concern[386]. - In February 2026, the company sold 12,560,715 shares of common stock and received net proceeds of approximately $4.5 million from the offering[390]. Business Operations - The company is developing the BRTX-100 product for chronic lower back pain and the ThermoStem Program for metabolic disorders, with several patents issued for these initiatives[362][363]. - The company does not believe that inflation had a material impact on its business or operating results during the reported periods[396]. - The company has no off-balance sheet arrangements that materially affect its financial condition or results of operations[400]. - The company’s critical accounting estimates are based on historical experience and reasonable assumptions, which may affect reported amounts of assets and liabilities[397].

Financial Performance - SKYX reported record annual revenue of $92 million in 2025, up from $86 million in 2024, marking an 8% year-over-year growth[1]. - The company generated $25 million in revenue in Q4 2025, compared to $24 million in Q4 2024, representing a 4% increase[4]. - Gross profit for 2025 increased to $28 million, a 13% rise from $25 million in 2024, with gross profit margin improving to 30%[6]. - Revenue for the year ended December 31, 2025, was $92,009,949, an increase of 6.4% compared to $86,276,876 in 2024[19]. - Operating expenses for 2025 totaled $121,122,339, up from $118,389,115 in 2024, indicating a 2.0% increase[19]. - Net loss attributed to common stockholders for 2025 was $34,474,779, compared to a net loss of $35,980,811 in 2024, reflecting a 4.2% improvement[19]. - The company reported a net loss per share of $0.32 for 2025, an improvement from a loss of $0.36 per share in 2024[19]. - Net loss for 2025 was $33,415,604, a slight improvement from a net loss of $35,768,144 in 2024, indicating a reduction of approximately 6.6%[21]. - Adjusted EBITDA for 2025 was $(11,375,344), improving from $(13,052,099) in 2024, reflecting a positive change of about 12.9%[23]. Cash Management - Operating cash used in 2025 was $13 million, down 27% from $18 million in 2024, indicating improved cash management[1]. - Total cash used in operating activities decreased to $13,291,059 in 2025 from $18,260,370 in 2024, representing a reduction of approximately 27.3%[21]. - Cash and cash equivalents decreased to $8,052,621 in 2025 from $12,639,441 in 2024, a reduction of 36.5%[18]. - Cash and cash equivalents at the end of 2025 were $10,102,621, down from $15,500,495 at the end of 2024, a decrease of about 34.9%[21]. - Net cash provided by financing activities decreased to $9,826,058 in 2025 from $13,062,040 in 2024, a decline of about 24.5%[21]. Assets and Liabilities - Total current assets decreased to $15,400,916 in 2025 from $20,374,450 in 2024, a decline of 24.5%[18]. - Total liabilities increased slightly to $57,303,620 in 2025 from $56,833,619 in 2024, representing a 0.8% increase[18]. - Total stockholders' equity (deficit) was $(4,588,386) in 2025, compared to $4,053,428 in 2024, indicating a significant decline[20]. - Inventory increased to $4,250,168 in 2025 from $3,785,346 in 2024, a rise of 12.3%[18]. - The weighted average number of common shares outstanding increased to 108,757,074 in 2025 from 99,766,866 in 2024, a growth of 9.9%[19]. Expenses - Interest expense increased to $4,303,214 in 2025 from $4,055,905 in 2024, marking an increase of approximately 6.1%[23]. - The company reported a depreciation and amortization expense of $4,320,338 in 2025, up from $4,066,957 in 2024, reflecting an increase of about 6.2%[23]. - Share-based payments remained relatively stable at $13,560,580 in 2025 compared to $13,474,433 in 2024, showing a marginal increase of 0.6%[23]. - The company did not incur any impairment of intangible assets in 2025, compared to an impairment of $1,118,750 in 2024[23]. - Proceeds from the issuance of common stock increased to $5,584,390 in 2025 from $4,426,222 in 2024, an increase of approximately 26.1%[21]. Future Outlook - The company expects to deploy over 100,000 products into homes/units by the end of 2026 through retail and professional segments[2]. - SKYX plans to launch a new AI-driven software for its e-commerce platform, which is anticipated to increase conversion rates and sales by up to 30%[3]. - The company is collaborating with NVIDIA to expand its smart home projects, aiming for significant growth in 2026[2]. - SKYX expects to supply over 1 million units of its advanced smart home technologies for key projects in the U.S. and globally[4]. - The company is progressing towards mandatory safety standardization for its ceiling outlet technology, which is expected to enhance market adoption and safety[7].

Financial Performance - Xos achieved positive operating cash flow and free cash flow of $2.4 million in Q4 2025, marking three consecutive quarters of cash-positive operations [2]. - Full-year operating expenses reduced by $14.0 million, or 28.2%, declining to $35.8 million from $49.8 million in 2024 [6]. - Operating loss narrowed by 27.9%, with a reported full-year operating loss of $33.1 million compared to $45.9 million in 2024 [6]. - EBITDA loss improved to $21.0 million from $42.2 million in 2024, reflecting a $21.2 million improvement [6]. - Revenues for Q4 2025 were $5,220,000, a decrease of 54.4% compared to $11,474,000 in Q4 2024 [25]. - Net loss for Q4 2025 was $9,752,000, compared to a net loss of $18,981,000 in Q4 2024, showing an improvement of 48.6% [25]. - Adjusted EBITDA for Q4 2025 was $(6,972,000), an improvement from $(11,957,000) in Q4 2024 [26]. - Free cash flow for Q4 2025 was $2,399,000, compared to $3,299,000 in Q4 2024, indicating a decrease of 27.2% [27]. - Gross profit for the twelve months ended December 31, 2025, was $2,724,000, down from $3,965,000 in 2024, a decline of 31.3% [25]. - Non-GAAP gross profit for Q4 2025 was $274,000, down from $2,667,000 in Q4 2024, a decline of 89.7% [29]. Production and Sales - Xos delivered 328 units in 2025, a 10% increase from 297 units in 2024, with revenue of $46.0 million compared to $56.0 million in 2024 [6]. - First production powertrains delivered for Blue Bird school buses, expanding into the school bus market [6]. - Xos plans to deliver between 350 to 500 units in 2026, with revenue forecasted between $40.0 million to $50.0 million [12]. Assets and Liabilities - Total current assets decreased to $49,877,000 in 2025 from $82,301,000 in 2024, representing a decline of 39.5% [23]. - Total liabilities decreased to $37,076,000 in 2025 from $64,723,000 in 2024, a reduction of 42.8% [23]. - Inventory reserves for Q4 2025 were $1,815,000, compared to $3,752,000 in Q4 2024, a decrease of 51.6% [28]. - The company reported a loss from operations of $(9,739,000) for Q4 2025, an improvement from $(14,572,000) in Q4 2024 [28]. Cash Position - Cash position strengthened to $14.0 million, up 28% from $11.0 million at year-end 2024 [6]. - Non-GAAP operating loss for 2026 is projected to be between $11.9 million to $13.3 million [12].

Financial Performance - INNOVATE Corp. reported consolidated revenue of $382.7 million for Q4 2025, a 61.7% increase from $236.6 million in Q4 2024[2] - The company's net loss attributable to common stockholders decreased to $7.8 million in Q4 2025, compared to a loss of $16.9 million in Q4 2024, marking a 53.8% improvement[12] - Total Adjusted EBITDA for Q4 2025 was $24.5 million, a 63.3% increase from $15.0 million in Q4 2024, driven primarily by the Infrastructure segment[12] - For Q4 2025, revenue was $382.7 million, a 61.5% increase from $236.6 million in Q4 2024; full-year revenue reached $1,246.0 million, up 12.6% from $1,107.1 million in 2024[33] - Gross profit for Q4 2025 was $58.9 million, compared to $46.4 million in Q4 2024, while full-year gross profit was $199.7 million, down from $208.8 million in 2024[33] - The net loss attributable to INNOVATE Corp. for Q4 2025 was $7.4 million, an improvement from a net loss of $16.6 million in Q4 2024; for the full year, the net loss was $60.6 million compared to $34.6 million in 2024[33] - Adjusted EBITDA for the three months ended December 31, 2025, was $24.5 million, compared to $15.0 million for the same period in 2024, reflecting a growth of 63.3%[37] - INNOVATE Corp. reported a net income of $29.5 million for the year ended December 31, 2025, compared to a net loss of $60.6 million in the same period of 2024[39] - Adjusted EBITDA for 2025 was $67.2 million, a decrease from $71.3 million in 2024, reflecting a decline of approximately 5.8%[39] Revenue Segments - The Infrastructure segment generated $373.9 million in revenue for Q4 2025, up 65.7% from $225.7 million in the prior year quarter, contributing significantly to overall growth[8] - The Spectrum segment reported a revenue decline to $5.7 million in Q4 2025 from $6.8 million in the prior year quarter, impacted by a softened advertising market[8] Cash and Assets - As of December 31, 2025, INNOVATE had cash and cash equivalents of $112.1 million, up from $48.8 million as of December 31, 2024[17] - Total current assets rose to $451.5 million in 2025, up from $390.9 million in 2024, which is an increase of 15.5%[35] - Total assets increased to $950.1 million in 2025, up from $891.1 million in 2024, representing a growth of 6.2%[35] - Current liabilities surged to $1,034.1 million in 2025, compared to $483.0 million in 2024, indicating a significant increase of 114.4%[35] - Total liabilities reached $1,165.4 million in 2025, up from $1,034.8 million in 2024, which is an increase of 12.6%[35] Operational Insights - INNOVATE's operating expenses for Q4 2025 were $45.0 million, slightly up from $44.8 million in Q4 2024, with selling, general and administrative expenses at $40.6 million[33] - The company reported a loss from operations before income taxes of $9.3 million in Q4 2025, an improvement from a loss of $14.9 million in Q4 2024[33] - DBM Global's gross margin was 14.7% in Q4 2025, a decrease of approximately 350 basis points year-over-year, indicating challenges in maintaining profitability[8] Future Outlook - INNOVATE is positioned for growth in 2026, supported by favorable contracts and ongoing trials with a major mobile wireless carrier[3] - The company plans to continue expanding its market presence and capitalize on potential growth opportunities in its strategic segments[26] - Forward-looking statements indicate expectations for future growth and performance in new projects and technologies, with a focus on advertising revenue growth and commercial opportunities in datacasting[26] - INNOVATE Corp. plans to focus on market expansion and new product development to drive future growth[39] - The company is actively pursuing acquisition opportunities to enhance its portfolio and market presence[39] Product Development - MediBeacon received FDA approval for the next generation MediBeacon TGFR System, enhancing the company's product offerings in Life Sciences[8] - R2 secured a minimum purchase agreement for 600 systems over three years in China, reflecting growing international demand[8] Interest and Expenses - Interest expense for the three months ended December 31, 2025, totaled $24.0 million, compared to $19.6 million in the same period of 2024, representing an increase of 22.4%[37] - The company incurred interest expenses totaling $89.0 million in 2025, up from $74.5 million in 2024, indicating a year-over-year increase of 19.8%[39] - Depreciation and amortization expenses were $17.5 million in 2025, slightly lower than $17.6 million in 2024[39] Losses and Deficits - The accumulated deficit increased to $(582.5) million in 2025 from $(521.9) million in 2024, indicating a deterioration of 11.6%[35] - The company reported a net loss in the Life Sciences segment of $3.5 million for Q4 2025, an improvement from a loss of $5.4 million in Q4 2024[37] - The company’s life sciences segment reported a net loss of $23.5 million in 2025, compared to a loss of $20.0 million in 2024, indicating a worsening performance[39] - The company reported a non-controlling interest loss of $3.4 million in 2025, compared to a loss of $5.1 million in 2024, showing a reduction of approximately 33.3%[39] - Realignment and exit costs amounted to $5.1 million in 2025, consistent with the $5.2 million reported in 2024[39]

Financial Performance - As of January 31, 2026, the project backlog for the Power segment was over $2.7 billion, up from approximately $1.3 billion as of January 31, 2025, indicating a significant increase in expected revenue from defined projects[24] - The Industrial segment's revenues were $167.6 million for Fiscal 2026, representing approximately 17.7% of consolidated revenues, consistent with the previous fiscal year[41] - Teledata segment revenues increased to $20.6 million in Fiscal 2026, accounting for approximately 2.2% of consolidated revenues, compared to $13.5 million in Fiscal 2025[49] - The Power segment's significant customer relationships accounted for approximately 23%, 16%, and 11% of consolidated revenues for Fiscal 2026, showing a shift from 28%, 13%, and 10% in Fiscal 2025[35] Financial Position - The company has a base lending commitment amount of $35.0 million under the Credit Agreement, with an additional accordion feature allowing for an extra commitment of $30.0 million[52] - As of January 31, 2026, the company had no borrowings outstanding under the Credit Agreement, with only a letter of credit issued for $0.3 million[53] - As of January 31, 2026, the company holds $150.0 million in certificates of deposit, $149.6 million in money market funds, and $402.5 million in U.S. Treasury notes, with a weighted average annual interest rate of 3.7%[271] - The company has a credit facility with a variable interest rate of SOFR plus 1.85%, with no outstanding borrowings as of January 31, 2026[272] - The company maintains material amounts of cash and short-term investments, with a commitment from the bank to issue standby letters of credit up to $60.0 million[58] - The weighted average number of days remaining until maturity for the company's certificates of deposit and U.S. Treasury notes was 963 days as of January 31, 2026[271] Risk Management - The company actively manages supply chain risks, which may cause delays in construction timelines and impact project costs due to material price fluctuations and tariffs[31] - Recent changes in U.S. trade policy have increased cost and supply chain uncertainty for construction materials, potentially affecting project costs and schedules[276] - The company is exposed to fluctuations in commodity prices, including steel, copper, concrete, and fuel, which may adversely affect results of operations[277] Workforce and Operations - The company employs 1,409 personnel as of January 31, 2026, with a focus on maintaining a stable and experienced workforce to support project execution[51] - The Industrial segment has emphasized the pursuit of larger field service construction projects and long-term fabrication projects in recent years[41] Safety and Governance - The reportable incident rates using OSHA methodology for the years 2021 to 2025 were 0.45, 0.56, 0.43, 0.60, and 0.48, respectively, indicating a commitment to workplace safety[55] - The responsible business committee of the board of directors oversees the company's strategy relating to environmental, health and safety, and corporate governance matters[59] Insurance and Financial Impact - The company has purchased specialty insurance related to the recovery of research and development tax credits claimed in prior fiscal years[57] - A hypothetical change of 100 basis points in interest rates would change annual investment earnings by $7.0 million[271] Competitive Landscape - The competitive landscape for the Power segment has seen a decline in capable competitors for domestic gas-fired power plant EPC work, potentially attracting new entrants due to growing demand[34]